Drug Profile
Peposertib - Merck KGaA
Alternative Names: M-3814; MSC-2490484A; NedisertibLatest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator Merck KGaA
- Developer EMD Serono Research & Development Institute; M. D. Anderson Cancer Center; Merck KGaA; National Cancer Institute (USA); Telix Pharmaceuticals; University of Kentucky
- Class Antineoplastics; Halogenated hydrocarbons; Morpholines; Pyridazines; Quinazolines; Small molecules
- Mechanism of Action DNA activated protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Rectal cancer; Small cell lung cancer
- Phase I Solid tumours
- No development reported Cancer; Chronic lymphocytic leukaemia; Glioblastoma; Neuroendocrine tumours
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for phase-I development in Cancer(In volunteers) in Germany (PO, Suspension)
- 28 Feb 2024 No recent reports of development identified for phase-I development in Cancer(In volunteers) in Germany (PO, Tablet)
- 28 Oct 2023 No recent reports of development identified for phase-I development in Glioblastoma(Combination therapy, In the elderly, Newly diagnosed, In adults) in USA (PO)